Fennec Pharmaceuticals (FENC) Net Cash Flow (2010 - 2025)

Fennec Pharmaceuticals (FENC) has 16 years of Net Cash Flow data on file, last reported at $14.8 million in Q4 2025.

• Quarterly Net Cash Flow rose 208.44% year-over-year to $14.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.2 million (down 24.03% YoY) and the FY2025 annual result came in at $10.2 million, down 24.03% from the prior year.
• Net Cash Flow rose to $14.8 million in Q4 2025, from $3.2 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $37.9 million in Q1 2024 to a low of -$13.7 million in Q4 2024.
• A 5-year average of $73800.0 and a median of -$3.3 million in 2021 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 804.22% in 2024, down 1673.1% in 2024.
• Tracing FENC's Net Cash Flow over 5 years: stood at -$3.2 million in 2021, then tumbled by 84.79% to -$6.0 million in 2022, then surged by 114.55% to $870000.0 in 2023, then slumped by 1673.1% to -$13.7 million in 2024, then surged by 208.44% to $14.8 million in 2025.
• The last three Net Cash Flow figures came in at $14.8 million (Q4 2025), $3.2 million (Q3 2025), and -$4.0 million (Q2 2025), per Business Quant data.